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Abstract Vasodilator-stimulated phosphoprotein (VASP), an
actin binding protein localized to areas of focal contacts, is a
substrate for the cyclic adenosine monophosphate/cyclic guano-
sine monophosphate (cAMP/cGMP)-dependent protein kinases
(PKA, PKG). In this study, we show that serum stimulation of
vascular smooth muscle cells (SMCs) induces VASP phosphor-
ylation on Ser157, in a mechanism not dependent on PKA or
PKG. We tested the possibility that protein kinase C (PKC), a
regulator of cytoskeletal function, is involved. PKC inhibition or
down-regulation prevented serum-induced phosphorylation of
VASP at Ser157 in rat vascular SMCs. Additionally, recombi-
nant PKCK directly phosphorylated Ser157 on VASP. In sum-
mary, our data support the hypothesis that PKC phosphorylates
VASP and mediates serum-induced VASP regulation.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Vasodilator-stimulated phosphoprotein (VASP), the ¢rst
identi¢ed member of the Ena/Mena/VASP family, is an actin
binding protein that is localized to focal adhesions and cell-to-
cell contacts [1,2]. VASP is present in numerous cell types
including platelets, endothelial cells, smooth muscle cells
(SMCs) and ¢broblasts [1,3]. Through highly conserved
EVH1 and EVH2 binding domains, VASP interacts directly
with F-actin, the Listeria surface protein, ActA, and the focal
adhesion proteins, vinculin, zyxin, and pro¢lin [2,4^7]. Vari-
ous studies describe a role for VASP in the assembly and
bundling of actin ¢laments, a dynamic process that mediates
cellular functions such as adhesion, motility, cell cycle pro-
gression, and contraction [8^12].
Studies using VASP-de¢cient mice have demonstrated en-
hanced platelet aggregation and diminished cyclic nucleotide-
mediated platelet inhibition, but no signi¢cant e¡ect on SMC
function such as contraction of isolated aorta and fundus
[13,14]. This lack of e¡ect may be explained by a potential
redundant role of the VASP-related protein Mena, which is
expressed in SMCs but absent in platelets. The role of VASP
in cellular motility has generated much debate. Recent studies
suggest that VASP may play a paradoxical role by increasing
lamellipodial velocity, while decreasing whole cell speed, in
part, through the inhibition of actin-capping proteins [12,
15,16].
VASP is phosphorylated on three sites by the cyclic aden-
osine monophosphate/cyclic guanosine monophosphate
(cAMP/cGMP)-dependent protein kinases, protein kinase A
(PKA) and protein kinase G (PKG) [17]. The preferred phos-
phorylation site for PKA is Ser157, which leads to a retarda-
tion of VASP mobility during sodium dodecyl sulfate (SDS)^
gel electrophoresis, resulting in an apparent shift in molecular
weight of VASP from 46 to 50 kDa. Phosphorylation of
Ser239 on VASP, the preferred site for PKG, as well as
Thr278 (a less favored site for both PKA and PKG), does
not alter VASP mobility during SDS^gel electrophoresis. To
date, the exact role of each of the three phosphorylation sites
is unclear. A positive correlation between the phosphorylation
of Ser157 on VASP and the inhibition of integrin KIIbL3 (¢-
brinogen receptor) activation in platelets is reported [18]. In
endothelial cells, PKG-induced phosphorylation resulted in
the detachment from focal adhesions of wild-type VASP,
but not of a mutant VASP containing Ser/Thr to Ala substi-
tutions at all three phosphorylation sites [19]. Phosphorylation
of Ser157 on VASP correlated with the detachment and
spreading of ¢broblasts and epithelial cells [20]. Further,
PKA-induced phosphorylation of VASP decreased actin nu-
cleation and binding, but had no e¡ect on the association of
VASP with vinculin, zyxin or pro¢lin [21]. Although the exact
function of VASP phosphorylation is not de¢ned, these stud-
ies suggest that discrete phosphorylation events may be crit-
ical for the regulation of VASP-mediated modulation of actin
cytoskeletal and focal adhesion-related processes.
To date, PKA and PKG are the only kinases known to
phosphorylate VASP. However, many protein kinases are in-
volved in the regulation of cytoskeletal and focal adhesion-
mediated events, including protein kinase C (PKC) family
members. For example, PKCN and PKCK interact with focal
adhesion proteins such as vinculin and talin, and PKC mem-
bers mediate actin^membrane interactions as well as integrin-
regulated signaling [22^25]. This study tested the hypothesis
that serum modulates VASP phosphorylation in a PKC-de-
pendent mechanism in vascular SMCs.
2. Materials and methods
2.1. Cell culture
Rat aortic SMCs were prepared as previously described [26]. Aortas
from Fischer 344 rats (3 months of age, Simonsen Laboratories, Gil-
roy, CA, USA) were isolated and enzymatically digested. Cells were
maintained in Dulbecco’s modi¢ed Eagle’s medium (DMEM) with
10% fetal bovine serum (serum; Gibco Life Technologies, Rockville,
MD, USA), and used at passages 5^9.
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2.2. Cell treatment and Western blot analysis
SMCs were plated at V150 000 cells/well using 6-well plates, and
grown to 70% con£uence in DMEM containing 10% serum. Serum-
containing DMEM was then replaced with serum-free DMEM for
2 days in order to achieve quiescence. Cells were treated with inhib-
itors of PKA (Rp-8-Br-cAMPS, 50^100 WM, BioLog-Life Science-In-
stitute and Calbiochem) and PKG (Rp-8-pCPT-cGMPS, 50 WM or
Rp-8-Br-PET-cGMPS, 50 WM, BioLog-Life Science-Institute and Cal-
biochem) or PKC (GF109203X, 10 WM; Go«6976, 10 WM; Go«6983,
5 WM; rottlerin, 10 WM; all from Calbiochem) prior to and during
stimulation with 10% serum or phorbol-12-myristate-13-acetate
(PMA, 1 WM). In some experiments, quiescent cells were incubated
with PMA (5 WM) or dimethyl sulfoxide (DMSO) vehicle for 24 h
prior to serum treatment. Cells were lysed in Laemmli bu¡er and
subjected to Western blot analysis as previously described [26]. Mem-
branes were probed with rabbit polyclonal anti-VASP (1:2000 dilu-
tion, Alexis Co.), mouse anti-phospho-Ser157 (as previously described
[27]), or mouse anti-phospho-Ser239 antibody (as previously described
[28]). Antibody detection was visualized using enhanced chemilumi-
nescence (Amersham Biosciences, Piscataway, NJ, USA) according to
manufacturer’s protocols.
2.3. In vitro kinase activity assay
Recombinant wild-type human VASP protein was prepared as pre-
viously described [28]. Wild-type VASP (0.1 Wg/reaction) was diluted
in ice-cold kinase bu¡er (10 mM magnesium chloride, 20 mM Tris^
HCl, pH 7.5) with recombinant PKCK (human active, 0.008 U/reac-
tion, Calbiochem). Calcium chloride (0.5 mM), a micelle suspension
of 0.3 mg/ml phosphatidylserine and 30 Wg/ml diacylglycerol, and
adenosine triphosphate (ATP) (100 WM ¢nal concentration) with or
without [Q32P]ATP (1 WCi/reaction), was added to initiate the kinase
reaction. Samples were incubated at 30‡C for 5 min, and the kinase
reaction stopped by the addition of four times Laemmli sample bu¡er.
Reactions containing [Q32P]ATP were run on 8% SDS^polyacrylamide
gels, and then ¢xed in 10% trichloroacetic acid and 1% sodium py-
rophosphate overnight. Gels were stained with Coomassie blue to
Fig. 1. Serum-induced phosphorylation of VASP at Ser157 is not dependent on PKA or PKG. A: Quiescent SMCs were treated for 1, 2, 4
and 6 h with serum (10%) and the phosphorylation of Ser157 and Ser239 on VASP examined by Western blot analysis. B: SMCs were treated
with Rp-8-Br-cAMPS (50 WM) or Rp-8-pCPT-cGMPS (50 WM), inhibitors of PKA and PKG, respectively, and the phosphorylation of VASP
on Ser157 in response to serum (10%) examined. C: Additionally, SMCs were treated with both Rp-8-Br-cAMPs (100 WM) and Rp-8-Br-PET-
cGMPS (50 WM) and VASP phosphorylation in response to serum examined (representative blot depicts duplicate samples). Attenuation of
VASP phosphorylation in response to the adenylate cyclase agonist, forskolin (1 WM), and the nitric oxide donor, SNAP (250 WM), by PKA
and PKG blockade, respectively, served as positive controls. Blots shown are representative of four independent experiments.
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identify the apparent molecular weight of VASP, dried, and radio-
labeled phosphate incorporation visualized on autoradiograph ¢lm.
Samples containing only non-radiolabeled ATP were loaded for
SDS^polyacrylamide gel electrophoresis (PAGE), transferred to nitro-
cellulose membrane, and probed with polyclonal antibody to VASP.
2.4. Statistical analysis
Western blots were quanti¢ed by densitometry (ImageQuant, Mo-
lecular Dynamics), and the ratio of phospho-Ser157 VASP to total
VASP was compared between each condition and analyzed statistical-
ly using one-way analysis of variance (ANOVA) with Student’s New-
man^Keuls post hoc test.
3. Results
3.1. Serum-induced phosphorylation of VASP at Ser157 does
not depend on PKA or PKG
The formation and regulation of focal adhesions and stress
¢bers is modulated by serum stimulation. We thus examined
the e¡ects of serum on the phosphorylation of VASP. Treat-
ment of quiescent rat vascular SMCs with serum (10%, 1^6 h)
resulted in VASP phosphorylation at Ser157, as determined
by a shift in the apparent molecular weight of VASP from 46
to 50 kDa upon SDS^PAGE, and by detection with a phos-
pho-speci¢c Ser157 VASP antibody (Fig. 1A). The serum-in-
duced phosphorylation peaked at 2 h, and was undetectable at
6 h after stimulation (Fig. 1A). Treatment with platelet-de-
rived growth factor BB and basic ¢broblast growth factor,
also induced phosphorylation of Ser157 on VASP (data not
shown). Treatment of SMCs with serum did not stimulate
phosphorylation of Ser239 on VASP (Fig. 1A). The e¡ect of
growth factor treatment on the regulation of Thr278 on
VASP, the third known phosphorylation site, was not simi-
larly examined by Western blot analysis due to lack of avail-
able antibodies to date.
Because both PKA and PKG phosphorylate Ser157 on
VASP, we investigated whether serum-induced phosphoryla-
tion of VASP is mediated by PKA or PKG. Pretreatment of
cells with Rp-8-Br-cAMPS (50 WM) or Rp-8-pCPT-cGMPS
(50 WM), inhibitors of PKA and PKG, respectively, had no
e¡ect on serum-induced phosphorylation of VASP on Ser157
(Fig. 1B). Treatment with Rp-8-Br-cAMPS or Rp-8-pCPT-
cGMPS, however, prevented VASP phosphorylation in re-
sponse to the adenylate cyclase agonist, forskolin, or an acti-
vator of soluble guanylate cyclase, the nitric oxide donor,
S-nitroso-n-acetylpenicillamine (SNAP), respectively (Fig. 1B).
To examine the possibility of overlapping functions of PKA
and PKG in mediating serum-induced VASP phosphoryla-
tion, quiescent SMCs were treated with both Rp-8-Br-cAMPS
(100 WM) and Rp-8-Br-PET-cGMPS (50 mM) (to inhibit
PKA and PKG, respectively), and the response to serum stim-
ulation tested. Concurrent blockade of PKA and PKG had no
e¡ect on the phosphorylation of VASP by serum (Fig. 1C).
Treatment with Rp-8-Br-cAMPS and Rp-8-Br-PET-cGMPS
did prevent forskolin and SNAP-induced VASP phosphoryla-
tion, respectively (Fig. 1C).
3.2. A PMA-sensitive isoform of PKC mediates serum-induced
VASP phosphorylation on Ser157
PKC regulates the formation of focal adhesions through
phosphorylation of various cytoskeletal proteins. We tested
whether PKC mediates serum-induced phosphorylation of
VASP on Ser157. Quiescent SMCs were treated for 24 h
with the phorbol ester, PMA (5 WM), in order to down-regu-
late PKC, or DMSO vehicle. Following treatment, cells were
stimulated with serum (10%) or forskolin (1 WM). Serum in-
duced phosphorylation of VASP at Ser157 in vehicle but not
in PMA-treated cells (Fig. 2A). However, forskolin (and
SNAP, 250 WM) induced VASP phosphorylation at Ser157
in both controls and PMA-treated cells (as shown for forsko-
lin in Fig. 2A). These data suggest that a PMA-sensitive iso-
form(s) of PKC mediates VASP phosphorylation on Ser157 in
response to serum.
We next sought to verify that activation of PKC induces
phosphorylation of Ser157 on VASP in SMCs. PKC was
stimulated by acute treatment of quiescent SMCs with
PMA. Treatment with PMA (1 WM, 30 min) resulted in phos-
phorylation of Ser157 on VASP (Fig. 2B). The PMA-induced
phosphorylation of VASP was completely blocked by inhibi-
tion of PKC with GF109203X (10 WM) (Fig. 2B). Phosphor-
ylation of Ser239 on VASP was not detected in response to
PMA stimulation (data not shown).
Fig. 2. A PMA-sensitive isoform of PKC is involved in phosphorylation of Ser157 on VASP. A: Quiescent SMCs were treated for 24 h with
PMA (5 WM) or DMSO before exposure to serum (10%) or forskolin (1 WM). Phosphorylation of VASP on Ser157 was detected by Western
blot analysis. B: Quiescent SMCs were treated with PMA (1 WM, 30 min) in the presence or absence of GF109203X (10 WM) and the phos-
phorylation of Ser157 on VASP examined. Blots shown are representative of four independent experiments.
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3.3. Serum-induced stimulation of Ser157 on VASP is
attenuated by inhibition of PKCK and L
Using inhibitors of various PKC isoforms, we sought to
determine which PKC isoform(s) mediates serum-induced
VASP phosphorylation. Treatment of rat vascular SMCs
with various PKC inhibitors, GF109203X (10 WM, to inhibit
PKCK, L, Q, N, and O), Go«6976 or Go«6983 (10 WM and 5 WM,
respectively, to inhibit the classical isoforms) [29^32], attenu-
ated serum-induced Ser157 phosphorylation on VASP
51S 5%, 63S 4% and 66S 10%, respectively (Fig. 3). How-
ever, treatment with the PKCN inhibitor, rottlerin (10 WM),
had no signi¢cant e¡ect on serum-induced Ser157 VASP
phosphorylation (Fig. 3). These data are consistent with the
involvement of diacylglycerol-dependent PKC, and suggest
that the K, L or Q isoform mediates serum-induced VASP
phosphorylation in rat vascular SMCs.
3.4. Recombinant PKCK directly phosphorylates VASP at
Ser157
We next examined whether PKCK directly phosphorylates
VASP. PKCK has been previously shown to account for the
majority of PKC activity in rat vascular SMCs, and may
localize to areas of focal adhesions [22^26]. Kinase activity
was ¢rst con¢rmed by the phosphorylation of myelin basic
protein by recombinant PKCK (data not shown). Further
analysis demonstrated human recombinant PKCK to phos-
phorylate recombinant human VASP, as detected by radio-
labeled phosphate incorporation corresponding to the appar-
ent molecular weights of 46 and 50 kDa (Fig. 4A). The higher
molecular weight band corresponded to the electrophoretic
mobility-shifted phosphorylated form of Ser157 on VASP.
No radiolabeled phosphate incorporation corresponding to
46^50 kDa by SDS^PAGE was detected in reactions lacking
either recombinant VASP or PKCK (Fig. 4A). Immunoblot
analysis with an antibody against total VASP demonstrated
activation of PKCK to result in a shift in wild-type VASP to
the 50 kDa form, indicative of phosphorylation of Ser157 on
VASP (Fig. 4B).
4. Discussion
A role for VASP in the regulation and modulation of focal
adhesions and the actin cytoskeleton has been suggested. In
this study, we show that serum treatment induces phosphor-
ylation of VASP on Ser157 in rat vascular SMCs, and dem-
onstrate this phosphorylation event to be mediated by PKC.
We further show that PKCK directly phosphorylates VASP,
introducing potential novel kinase involved in the regulation
of VASP.
Fig. 3. Serum-induced phosphorylation of VASP at Ser157 is medi-
ated by PKCK or L. Quiescent SMCs were treated for 30 min with
inhibitors of PKC: GF109203X (10 WM), Go«6983 (5 WM), Go«6976
(10 WM), or rottlerin (10 WM), prior to and during stimulation with
serum (10%) and the phosphorylation of Ser157 on VASP examined
by Western blot analysis. A: Representative Western blot. B: Phos-
phorylated Ser157 on VASP as a percent of the serum-stimulated
control response. The percent of VASP that was phosphorylated
Ser157 was calculated from arbitrary densitometry units as a ratio
of phosphorylated Ser157 (50 kDa band) divided by total VASP (50
kDa band+46 kDa band). Graph of results from four to six inde-
pendent experiments; *P6 0.05, ANOVA.
Fig. 4. Recombinant PKCK directly phosphorylates recombinant hu-
man VASP. Kinase activity of recombinant PKCK was initiated by
the addition of phospholipids and ATP, and the phosphorylation of
recombinant VASP (46^50 kDa bands) measured through analysis
of radiolabeled phosphate incorporation or by immunoblotting with
antibody against VASP (kinase reaction run at 30‡C, 5 min).
A: Autoradiograph of [32P]phosphate incorporation and correspond-
ing Coomassie-stained gel. Radiolabeled phosphate incorporation
was not detected in the 46^50 kDa molecular weight bands in reac-
tions lacking substrate or enzyme. Incorporation of radiolabeled
phosphate corresponding to V80 kDa may be indicative of auto-
phosphorylation of PKCK, and is absent in reactions in which no
enzyme was added. B: Western blot probed with polyclonal anti-
body against VASP.
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In rat vascular SMCs, serum-induced VASP phosphoryla-
tion is not inhibited by blockade of PKA or PKG, the known
VASP kinases to date, but is prevented by inhibition of PKC
(Figs. 1^3). Additionally, activation of PKC with the phorbol
ester, PMA, induces phosphorylation of Ser157 on VASP, in a
GF109203X-sensitive manner (Fig. 2B). In HEK 293 cells,
PMA-induced phosphorylation of VASP is inhibited by
blockade of PKG [33]. However, in our study, inhibition of
PKG does not prevent PMA-induced VASP phosphorylation
of rat vascular SMCs, which may indicate cell-type speci¢c
regulation of VASP (data not shown).
PKC mediates the formation and regulation of focal adhe-
sions in response to cell adhesion and growth factor stimula-
tion [22,24,25]. Our data in rat vascular SMCs suggest that a
classical, diacylglycerol-dependent isoform of PKC mediates
serum-induced VASP phosphorylation. The K isoform of
PKC has been shown to account for the majority of PKC
activity in rat vascular SMCs [26]. Thus, we examined
PKCK-induced phosphorylation of VASP, but do not exclude
the possibility that the L isoform(s) of PKC plays a role in
VASP regulation (PKCQ is not found in detectable levels in
rat vascular SMCs [26]). The in vitro phosphorylation of re-
combinant human VASP by PKCK results in the incorpora-
tion of radiolabeled phosphate at the apparent molecular
weights of 46 and 50 kDa during SDS^PAGE (Fig. 4A).
The upper 50 kDa band corresponds to that of VASP phos-
phorylated on Ser157. However, the signi¢cance of the radio-
labeled phosphate incorporation at the position of the lower
46 kDa band is unclear, as it may indicate phosphorylation of
additional sites on VASP, such as Thr278 or a yet unidenti¢ed
site.
PKC is established to modulate focal adhesions and stress
¢bers through numerous mechanisms. The K isoform of PKC
is translocated to focal adhesions upon integrin KIIbL3 activa-
tion of the ¢bronectin receptor, and is reported to phosphor-
ylate focal adhesion proteins such as vinculin and talin [23^
25,34]. Additionally, PKC modulates the cellular cytoskeleton
through the regulation of intermediate ¢lament and stress
¢ber-related proteins, including vimentin, CPI-17, myosin
light chain kinase, tau and numerous others [24,35]. The re-
sults of this study suggest that PKCK phosphorylates VASP,
demonstrating a novel cytoskeleton-associated substrate for
PKC and a potential additional mechanism of PKC-mediated
focal adhesion/stress ¢ber regulation.
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